Johnson & Johnson Upgraded to “Outperform” at Raymond James Following Synthes Merger Approval, $12.9 Billion Share Buyback (JNJ)

By
A A A
Share |

Diversified healthcare giant Johnson & Johnson ( JNJ ) on Wednesday caught a big upgrade from analysts at Raymond James.

The firm said it boosted its rating on JNJ from "Market Perform" to "Outperform." The move comes following J&J's announcement late Tuesday that its proposed $19.7 billion cash/stock acquisition of Swiss medical device maker Synthes has received regulatory approval.

In pursuant to the deal, J&J's Janssen unit will begin repurchasing up to $12.9 billion of JNJ's common stock.

Johnson & Johnson shares rose $1.32, or +2.1%, in premarket trading Wednesday.

The Bottom Line
We began recommending shares of Johnson & Johnson ( JNJ ) on Apr.27, when the stock was trading at $64.75. The company has a 3.87% dividend yield, based on last night's closing stock price of $63.08.

Johnson & Johnson ( JNJ ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: JNJ

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

80%

Most Active by Volume

110,219,031
  • $6.79 ▲ 14.31%
104,982,008
  • $11.83 ▲ 12.35%
95,065,355
  • $3.40 ▲ 0.59%
79,694,763
  • $36.59 ▲ 2.64%
49,037,292
  • $39.90 ▲ 5.81%
47,069,528
  • $15.34 ▼ 1.03%
43,387,835
  • $6.56 ▼ 1.94%
42,066,487
  • $98.38 ▼ 0.65%
As of 7/29/2014, 04:04 PM